Pro-Pharmaceuticals (PRW) Receives FDA IND Application for Use of DAVANAT(R)
Pro-Pharmaceuticals, Inc. (Amex: PRW), today announced that the U.S. FDA has granted an Investigational New Drug application for use of DAVANAT(R) in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. DAVANAT(R) also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.
Pre-clinical studies showed that DAVANAT(R), in combination with chemotherapy, significantly reduced tumor growth in mice implanted with metastatic human breast cancer. Results from similar pre-clinical studies designed to optimize formulations of DAVANAT(R) and 5-FU also lowered toxicity as indicated by the weight gain of the mice in the study.
Pro-Pharmaceuticals, Inc., a development stage life sciences company, engages in the discovery, development, and commercialization of targeted therapeutic compounds for the treatment of cancer, liver, microbial, and inflammatory diseases.
Pre-clinical studies showed that DAVANAT(R), in combination with chemotherapy, significantly reduced tumor growth in mice implanted with metastatic human breast cancer. Results from similar pre-clinical studies designed to optimize formulations of DAVANAT(R) and 5-FU also lowered toxicity as indicated by the weight gain of the mice in the study.
Pro-Pharmaceuticals, Inc., a development stage life sciences company, engages in the discovery, development, and commercialization of targeted therapeutic compounds for the treatment of cancer, liver, microbial, and inflammatory diseases.
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
